Login to Your Account



Clinic Roundup


Thursday, January 24, 2013
• EntreMed Inc., of Rockville, Md., said it started a Phase II study, titled "A Phase II Study of Oral ENMD-2076 Administered to Patients with Advanced/Metastatic Soft Tissue Sarcoma." ENMD-2076 is designed to inhibit both Aurora kinase A and angiogenesis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription